CCX559 is a potent orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity.

被引：0
|
作者：
Li, Chris [1 ]
Vilalta, Marta [1 ]
Ertl, Linda S. [1 ]
Wang, Yu [1 ]
Zeng, Yibin [1 ]
Fan, Pingchen [1 ]
Lange, Christopher [1 ]
McMurtrie, Darren [1 ]
Yang, Ju [1 ]
Lui, Rebecca [1 ]
Scamp, Ryan [1 ]
Chhina, Vicky [1 ]
Kumamoto, Alice [1 ]
Ong, Ryan [1 ]
Dang, Ton [1 ]
Easterday, Ashton [1 ]
Zhao, Niky [1 ]
Liu, Shirley [1 ]
Singh, Rajinder [1 ]
Charo, Israel [1 ]
Sullivan, Kathleen [1 ]
Schall, Thomas J. [1 ]
Zhang, Penglie [1 ]
机构：
[1] ChemoCentryx, Mountain View, CA USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1274
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
    Koblish, Holly K.
    Wu, Liangxing
    Wang, Liang-Chuan S.
    Liu, Phillip C. C.
    Wynn, Richard
    Rios-Doria, Jonathan
    Spitz, Susan
    Liu, Hao
    Volgina, Alla
    Zolotarjova, Nina
    Kapilashrami, Kanishk
    Behshad, Elham
    Covington, Maryanne
    Yang, Yan-Ou
    Li, Jingwei
    Diamond, Sharon
    Soloviev, Maxim
    O'Hayer, Kevin
    Rubin, Stephen
    Kanellopoulou, Chrysi
    Yang, Gengjie
    Rupar, Mark
    DiMatteo, Darlise
    Lin, Luping
    Stevens, Christina
    Zhang, Yue
    Thekkat, Pramod
    Geschwindt, Ryan
    Marando, Cindy
    Yeleswaram, Swamy
    Jackson, Jeff
    Scherle, Peggy
    Huber, Reid
    Yao, Wenqing
    Hollis, Gregory
    CANCER DISCOVERY, 2022, 12 (06) : 1482 - 1499
  • [32] A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity
    Albu, Diana I.
    Wolf, Benjamin J.
    Qin, Yan
    Wang, Xianzhe
    Ulumben, Amy Daniel
    Su, Mei
    Li, Vivian
    Ding, Eirene
    Gonzalo, Jose Angel
    Kong, Jason
    Jadhav, Ruturaj
    Kuklin, Nelly
    Visintin, Alberto
    Gong, Bing
    Schuetz, Thomas J.
    ONCOIMMUNOLOGY, 2024, 13 (01):
  • [33] Highly potent, orally active novel small-molecule HPK1 inhibitor DS21150768 induces anti-tumor responses in multiple syngeneic tumor mouse models
    Setsu, Genzui
    Goto, Megumi
    Ito, Kentaro
    Taira, Tomoe
    Miyamoto, Masaya
    Watanabe, Tomohiro
    Taniguchi, Toru
    Umezaki, Yuma
    Nakazawa, Yusuke
    Uesugi, Shuhei
    Mori, Kazuki
    Horiuchi, Takao
    Obuchi, Wataru
    Minami, Masako
    Shimada, Takashi
    Wada, Chisa
    Yoshida, Takanori
    Higuchi, Saito
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2023, 961
  • [34] Hsc70 promotes anti-tumor immunity by targeting PD-L1 for lysosomal degradation
    Xu, Xiaoyan
    Xie, Tingxue
    Zhou, Mengxin
    Sun, Yaqin
    Wang, Fengqi
    Tian, Yanan
    Chen, Ziyan
    Xie, Yanqi
    Wu, Ronghai
    Cen, Xufeng
    Zhou, Jichun
    Hou, Tingjun
    Zhang, Lei
    Huang, Chaoyang
    Zhao, Qingwei
    Wang, Dongrui
    Xia, Hongguang
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [35] ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation
    Youqian Wu
    Chao Zhang
    Xiaolan Liu
    Zhengfu He
    Bing Shan
    Qingxin Zeng
    Qingwei Zhao
    Huaying Zhu
    Hongwei Liao
    Xufeng Cen
    Xiaoyan Xu
    Mengmeng Zhang
    Tingjun Hou
    Zhe Wang
    Huanhuan Yan
    Shuying Yang
    Yaqin Sun
    Yanying Chen
    Ronghai Wu
    Tingxue Xie
    Wei Chen
    Ayaz Najafov
    Songmin Ying
    Hongguang Xia
    Nature Communications, 12
  • [36] Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation
    Shi, Chengyu
    Wang, Ying
    Wu, Minjie
    Chen, Yu
    Liu, Fangzhou
    Shen, Zheyuan
    Wang, Yiran
    Xie, Shaofang
    Shen, Yingying
    Sang, Lingjie
    Zhang, Zhen
    Gao, Zerui
    Yang, Luojia
    Qu, Lei
    Yang, Zuozhen
    He, Xinyu
    Guo, Yu
    Pan, Chenghao
    Che, Jinxin
    Ju, Huaiqiang
    Liu, Jian
    Cai, Zhijian
    Yan, Qingfeng
    Yu, Luyang
    Wang, Liangjing
    Dong, Xiaowu
    Xu, Pinglong
    Shao, Jianzhong
    Liu, Yang
    Li, Xu
    Wang, Wenqi
    Zhou, Ruhong
    Zhou, Tianhua
    Lin, Aifu
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [37] ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation
    Wu, Youqian
    Zhang, Chao
    Liu, Xiaolan
    He, Zhengfu
    Shan, Bing
    Zeng, Qingxin
    Zhao, Qingwei
    Zhu, Huaying
    Liao, Hongwei
    Cen, Xufeng
    Xu, Xiaoyan
    Zhang, Mengmeng
    Hou, Tingjun
    Wang, Zhe
    Yan, Huanhuan
    Yang, Shuying
    Sun, Yaqin
    Chen, Yanying
    Wu, Ronghai
    Xie, Tingxue
    Chen, Wei
    Najafov, Ayaz
    Ying, Songmin
    Xia, Hongguang
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [38] Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
    Topalian, Suzanne L.
    Drake, Charles G.
    Pardoll, Drew M.
    CURRENT OPINION IN IMMUNOLOGY, 2012, 24 (02) : 207 - 212
  • [39] Novel small molecule HPK1 inhibitor induces immunogenic anti-tumor effects.
    Chaudhari, Sachin S.
    Bajpai, Malini
    Mandadi, Sravan
    Kattige, Vidya G.
    Thorat, Sandeep
    Potdar, Varada
    Pangre, Priyanka
    Sawant, Pooja
    Misra, Chandrasekhar
    Das, Subhadip
    Akarte, Atul
    Singh, Anuj
    Mahankali, Sandeep
    Lambade, Pandurang
    Das, Avratanu
    Patole, Raju
    Udupa, Venkatesha
    Sancheti, Pavankumar
    Pawar, Pramod K.
    Kakade, Somesh
    Vinod, K. R.
    Biswas, Nilanjana
    Shah, Heta
    Behera, Dayanidhi
    Jain, Pankaj
    Gowda, Nagaraj
    Iyer, Pravin S.
    CANCER RESEARCH, 2021, 81 (13)
  • [40] A novel PIKfyve inhibitor, CB371 enhances the anti-tumor activity of anti-PD-1 antibody by modulating cancer immunity.
    Uno, Yuko
    Matsumoto, Hirokazu
    Endo, Hiroko
    Katoh, Yuki
    Yaguchi, Tomonori
    Kawakami, Yutaka
    Sawa, Masaaki
    CANCER SCIENCE, 2022, 113 : 1626 - 1626
12345